[1P-0670] Lobeglitazone, Antidiabetic drug, protects mice from lipogenesis-induced liver injury via inhibiting mTORC1

〇Yu Seol Lee^1,2, Jeong Su Park¹, Da Hyun Lee^1,2, Dong-Kyu Lee³, Sung Won Kwon^3,4, Byung-Wan Lee⁵, Soo Han Bae¹ (1.Severance Biomedical Science Institute, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, 2.Brain Korea 21 PLUS Project for Medical Science, Yonsei University, 3.Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea, 4.College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea, 5.Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea)

Lobeglitazone, Thiazolidinedione, NAFLD, hepatic steatosis